Enhanced tumor delivery and antitumor response of doxorubicin loaded albumin nanoparticles formulated based on a Schiff base
Fang Li,1,2,* Chunli Zheng,1,* Junbo Xin,2 Fangcheng Chen,1 Hua Ling,3 Linlin Sun,4 Thomas J Webster,4,5 Xin Ming,6 Jianping Liu1 1School of Pharmacy, China Pharmaceutical University, Nanjing, 2School of Pharmacy, Yancheng Vocational Institute of Health Sciences, Yancheng, People’s Republi...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ba669ff6f7c84335bf46ae752aae6acc |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Fang Li,1,2,* Chunli Zheng,1,* Junbo Xin,2 Fangcheng Chen,1 Hua Ling,3 Linlin Sun,4 Thomas J Webster,4,5 Xin Ming,6 Jianping Liu1 1School of Pharmacy, China Pharmaceutical University, Nanjing, 2School of Pharmacy, Yancheng Vocational Institute of Health Sciences, Yancheng, People’s Republic of China; 3School of Pharmacy, Hampton University, Hampton, VA, 4Department of Chemical Engineering, Northeastern University, Boston, MA, USA; 5Center of Excellence for Advanced Materials Research, King Abdulaziz University, Jeddah, Saudi Arabia; 6Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA *These authors contributed equally to this work Abstract: A novel method was developed here to prepare albumin-based nanoparticles (NPs) for improving the therapeutic and safety profiles of chemotherapeutic agents. This approach involved crosslinking bovine serum albumin (BSA) using a Schiff base-containing vanillin, into NPs and loading doxorubicin (DOX) into the NPs by incubation. The resultant NPs (DOX-BSA-V-NPs) displayed a particle size of 100.5±1.3 nm with a zeta potential of –23.05±1.45 mV and also showed high drug-loading efficiency and excellent stability with respect to storage and temperature. The encapsulation of DOX into the BSA-V-NPs was confirmed by dynamic scanning calorimetry and Raman spectroscopy. DOX-BSA-V-NPs exhibited a significantly faster DOX release at pH 6.5 than pH 7.4, as well as in a solution with a higher glutathione concentration. In vitro studies showed that the cellular uptake of DOX-BSA-V-NPs was time-dependent, concentration-dependent, and faster than free DOX, while the cytotoxicity of DOX-BSA-V-NPs (IC50 value of 3.693 µg/mL) was superior to free DOX (IC50 value of 4.007 µg/mL). More importantly, DOX-BSA-V-NPs showed a longer mean survival time of 24.83 days, a higher tumor inhibition rate of 56.66%, and a decreased distribution in the heart than other DOX formulations in animal studies using a tumor xenograft model. Thus, the vanillin-based albumin NPs were shown here to be a promising carrier for tumor-targeted delivery of chemotherapeutic agents and, thus, should be further studied. Keywords: doxorubicin, albumin nanoparticles, Schiff base, tumor delivery, anticancer response |
|---|